Diabetic Macular Oedema Initial PBS authority application Supporting information form (PB155)

You must lodge this form for a patient starting initial Pharmaceutical Benefits Scheme (PBS) subsidised treatment with ranibizumab or aflibercept for the treatment of visual impairment due to Diabetic Macular Oedema (DMO).

 

Page last updated: 5 February 2016

This information was printed Sunday 25 September 2016 from humanservices.gov.au/health-professionals/forms/pb155 It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.